Rituximab-based regimens for primary cardiac lymphoma: A systematic review of outcomes, challenges and future directions

Table 1 Characteristics of the studies included in this systematic review

Ref.	Country	No. of patients	Gender	Age (years)
Ellen and Emma[17], 2023	Ireland	1	Female	78
Qiang et al[18], 2022	China	1	Male	71
Mao et al[19], 2023	China	1	Male	64
Fuseya et al[20], 2021	Japan	1	Male	54
Miyawaki et al[21], 2021	Japan	1	Male	55
Fukuzaki et al[22], 2022	Japan	1	Female	68
Mandal et al[13], 2019	Cyprus	1	Male	83
Bonou et al[23], 2019	Greece	1	Male	28
Anand et al[24], 2019	United States	1	Male	69
Ito et al[25], 2018	Japan	1	Male	79
Endo et al[26], 2018	Japan	1	Male	79
Mendelson et al[27], 2018	United States	1	Male	79
Annibali et al[28], 2018	Italy	1	Male	80
Quiroz et al[29], 2018	United States	1	Female	85
Rogers et al[30], 2016	United States	1	Male	72
Soon et al[31], 2016	Singapore	3	Female; Female; Male	80F; 75F; 59M
Yamamoto et al[32], 2016	Japan	1	Male	65
Montanaro et al[33], 2015	United States	1	Male	71
Khan-Kheil et al[34], 2015	United Kingdom	1	Male	71
Pires Ferreira Filho et al[5], 2015	Brazil	1	Male	52
Nose et al[35], 2014	Japan	1	Female	80
Habertheuer et al[36], 2014	Austria	1	Female	70
Tzachanis et al[6], 2014	United States	1	Female	44
Menke et al[37], 2012	Germany	1	Male	56
Gadage et al[38], 2011	India	1	Male	38
Bambury et al[39], 2011	Ireland	1	Female	70
Shin et al[40], 2010	Korea	1	Male	59
Fujita et al[41], 2009	Japan	1	Male	56
Nonami et al[12], 2007	Japan	1	Female	55
Trost et al[42], 2007	United States	1	Female	83
Dawson et al[14], 2006	Australia	1	Female	76
Bley et al[43], 2005	Germany	1	Female	76
Anghel et al[44], 2004	Italy	2	Male; Female	52M; 70F